Honokiol regulates Acute respiratory distress syndrome (ARDS)-associated pulmonary fibrosis via the miR-19a-3p/POSTN axis.

Summary

In patients with ARDS, serum POSTN was elevated and miR-19a-3p was reduced, with both markers associated with disease severity. In an LPS-induced mouse model and macrophage-based co-culture systems, honokiol attenuated lung injury and fibrotic responses, while reporter and loss-of-function experiments supported regulation through the miR-19a-3p/POSTN axis.

Key Findings

• Patients with ARDS had increased serum POSTN and decreased miR-19a-3p, with inverse correlation and associations with disease severity.
• Honokiol reduced LPS-induced lung injury and fibrotic responses in mice and preserved miR-19a-3p while lowering POSTN expression.
• Reporter, co-culture, and loss-of-function experiments supported macrophage-related regulation of epithelial apoptosis and fibroblast activation through the miR-19a-3p/POSTN axis.

Clinical Implications

The miR-19a-3p/POSTN axis may support biomarker-guided risk stratification and therapeutic development for ARDS-associated fibrosis. Honokiol should be regarded as a preclinical candidate requiring pharmacokinetic, safety, dose-finding, and prospective clinical studies rather than as an established treatment.

Limitations

• The abstract does not report the size or detailed design of the patient cohort, limiting assessment of clinical biomarker validity.
• The evidence is based on LPS-induced injury and cell models; pharmacokinetics, toxicity, optimal dosing, and efficacy in human ARDS were not established.

Future Directions

Future work should validate POSTN and miR-19a-3p prospectively in well-characterized ARDS cohorts, define the cellular source and temporal behavior of the pathway, and conduct pharmacokinetic, toxicology, dose-finding, and randomized clinical studies of honokiol or more selective pathway modulators.